Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Sequential Intravesical Valrubicin and Docetaxel for the Salvage Treatment OF NON-MUSCLE Invasive Bladder CancerJ Urol 2022 Jul 05;[EPub Ahead of Print], IM McElree, VT Packiam, RL Steinberg, SL Mott, PT Gellhaus, KG Nepple, MA O'Donnell
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.